Four months after GPC Biotech AG's satraplatin met its endpoint in a pivotal prostate cancer study, the company pulled in €33.6 million (US$43.7 million) to pave the way for the compound's anticipated commercialization. (BioWorld Today)
Applied NeuroSolutions Inc. (APNS) will receive $2 million up front in an early stage partnership with Eli Lilly and Co. focused on developing drugs targeting an underlying cause of Alzheimer's disease. (BioWorld Today)
